SynthesisCalcified tissue international2025
A Systematic Review of the Effects of Bisphosphonates on Osteoblasts In Vitro.
Synthesis in Calcified tissue international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Photobiomodulation Modulates the Response of Zoledronic-Acid-Treated Osteoblast-like SaOs-2 Cells: Implications for Bisphosphonate-Related Osteonecrosis.Bioengineering (Basel, Switzerland) · 2026Article
- [Antiresorptive therapies in osteoporosis].Orthopadie (Heidelberg, Germany) · 2025Review
- Engineering a BMP2-risedronate complex with sustained release for osteoporosis therapy.Archives of pharmacal research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bisphosphonates (BPs) are widely used to treat bone disorders, prevent skeletal-related events, and manage bone metastasis. These drugs are synthetic analogs of pyrophosphate and primarily function by inhibiting osteoclast activity. However, increasing evidence suggests that they also have an effect on osteoblasts. This systematic review aims to evaluate how bisphosphonates affect osteoblasts by summarizing findings from in vitro studies on the impact of BPs on osteoblast lineage cells, addressing the following question: "Do bisphosphonates affect osteoblast cell lineage function?". For this purpose, the PICO framework was followed, and 36 articles were selected for inclusion in this review. The data suggest that the molecular mechanisms in osteoblasts can vary depending on the specific type of bisphosphonate, as well as the concentration and duration of treatment, leading to either stimulation or inhibition of osteogenesis. Additionally, studies have shown that certain BPs, such as zoledronic acid, can interfere with osteoblast differentiation, proliferation, gene expression, and mineralization capacity, potentially impairing bone healing. On the other hand, other drugs, such as alendronate, demonstrate more positive effects on cell function. Some drugs, such as pamidronate and clodronate, exhibited mixed effects; however, it was observed that high concentrations of these drugs can lead to cytotoxic effects. Despite these adverse effects, it is important to recognize that the clinical benefits of managing bone disorders often outweigh the potential risks highlighted in this review.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.